Abstract
L-2-Oxothiazolidine-4-carboxylic acid (OTC) is a cysteine prodrug that maintains glutathione in tissues. The present study was designed to investigate anti-fibrotic and anti-oxidative effects of OTC via modulation of nuclear factor erythroid 2-related factor 2 (Nrf2) in an in vivo thioacetamide (TAA)-induced hepatic fibrosis model. Treatment with OTC (80 or 160 mg/kg) improved serum liver function parameters and significantly ameliorated liver fibrosis. The OTC treatment groups exhibited significantly lower expression of α-smooth muscle actin, transforming growth factor-β1, and collagen α1 mRNA than that in the TAA model group. Furthermore, the OTC treatment groups showed a significant decrease in hepatic malondialdehyde level compared to that in the TAA model group. Nrf2 and heme oxygenase-1 expression increased significantly in the OTC treatment groups compared with that in the TAA model group. Taken together, these results suggest that OTC restores the anti- oxidative system by upregulating Nrf2; thus, ameliorating liver injury and a fibrotic reaction.
| Original language | English |
|---|---|
| Pages (from-to) | 348-353 |
| Number of pages | 6 |
| Journal | BMB Reports |
| Volume | 45 |
| Issue number | 6 |
| DOIs | |
| State | Published - 2012.06 |
Keywords
- L-2-Oxothiazolidine-4-carboxylic acid
- Liver fibrosis
- Nrf2
- Oxidative stress
- Thioacetamide
Quacquarelli Symonds(QS) Subject Topics
- Biological Sciences
Fingerprint
Dive into the research topics of 'Anti-fibrotic effects of L-2-oxothiazolidine-4-carboxylic acid via modulation of nuclear factor erythroid 2-related factor 2 in rats'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver